3654 results for «209»

Filter By

3654 results

Bifurcation failure: the realities and strategies for avoidance

21 May 2026 – From EuroPCR 2026

This session addresses the challenges associated with bifurcation lesion PCI, focusing on procedural complications, novel classification systems for in-stent restenosis, and plaque characterization near side branches. It reviews clinical outcomes of Drug-Coated Balloon (DCB) treatments for side branch lesions, the influence of drug-eluting balloon strategies, and...

Multivessel complications: what can go wrong

21 May 2026 – From EuroPCR 2026

This session highlights complications encountered in multivessel coronary interventions, presenting complex cases such as lost stents, coronary perforations, shaft fractures, early subacute stent thrombosis, and rare triple vessel thrombosis. It emphasizes practical management strategies for these challenging scenarios in contemporary interventional cardiology.

Multivessel complications: what can go wrong

New data on intracoronary imaging-guided interventions

21 May 2026 – From EuroPCR 2026

This session presents new data on intracoronary imaging-guided interventions, comparing outcomes of angiography-derived FFR and IVUS-guided PCI over two years, as well as OCT versus IVUS for intermediate left main stenosis. It further evaluates high-risk non-culprit lesions post-myocardial infarction, the role of coronary lipid burden in...

New data on intracoronary imaging-guided interventions

All you need to know of DAPT in ACS

21 May 2026 – From EuroPCR 2026

This session provides an in-depth review of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS), focusing on strategies for safe de-escalation and P2Y12 inhibitor monotherapy to reduce bleeding risk without compromising ischemic protection. It also covers optimizing antithrombotic therapy in patients on oral anticoagulation and...

All you need to know of DAPT in ACS

A series of complex real-word challenges STEMI treatment from very different countries

21 May 2026 – From EuroPCR 2026

This session showcases a series of complex STEMI treatment challenges from diverse international settings, highlighting difficult coronary anatomies and complicated procedures. It discusses nuanced clinical scenarios where artery recanalisation does not always equate to reperfusion, and presents stepwise approaches to managing multivessel disease, renal failure, and...

Bifurcation and heavily calcified lesions

21 May 2026 – From EuroPCR 2026

This session addresses the evaluation and treatment of bifurcation and heavily calcified coronary lesions. It includes case-based discussions on complex left main PCI and the use of drug-coated balloons (DCB) for bifurcation lesions and in-stent restenosis, providing evidence-based approaches to optimize outcomes in these challenging lesion...

New evidence in coronary physiology for microvascular assessment

21 May 2026 – From EuroPCR 2026

This session highlights new evidence in coronary physiology related to microvascular assessment. Topics include endothelial dysfunction in angina with non-obstructive arteries, the prognostic value of microvascular resistance metrics, natural history studies, and trials aimed at standardizing management of microvascular dysfunction.

New evidence in coronary physiology for microvascular assessment

PFO closure - Progression in practice

20 May 2026 – From EuroPCR 2026

This session presents progressive insights into patent foramen ovale (PFO) closure, comparing outcomes across age groups and evaluating residual shunting via transcranial Doppler. It highlights tailored antiplatelet therapy durations from the PROLONG registry, long-term safety and efficacy data, morphological variations of the fossa ovalis, and the...

MASTER-DAPT: “the MASTER of high-bleeding risk trials”

28 Aug 2021

Marco Valgimigli (Lugano, Switzerland) presented the results of the MASTER DAPT trial on Saturday, August 28, in a Hot Line session of the ESC Congress 2021. Luis G. Ortega-Paz provides his PICOT & SWOT analysis of this study.

Luis Ortega-Paz

Author

Luis Ortega-Paz
ESC Congress 2021 - MASTER-DAPT : “the MASTER of high-bleeding risk trials”

On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial

05 Mar 2023

Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial

SMT’s Hydra TAVR Valve demonstrates sustained safety, durability, and hemodynamic performance at 5 Years

19 Nov 2025

TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation

04 Nov 2024

Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.

Also watch the interview with Susheel K. Kodali

Alessandro Sticchi

Author

Alessandro Sticchi
TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation

Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR

29 Mar 2025

Daniele Giacoppo and Nicola Ammirabile provide their take on the main results of the HOST-BR trial, presented by Hyo-Soo Kim at ACC.25 in Chicago.

Nicola Ammirabile

Author

Nicola Ammirabile
Daniele Giacoppo

Author

Daniele Giacoppo
Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR

HOST-EXAM:10-year follow-up of clopidogrel vs aspirin monotherapy in stable CAD after PCI with drug-eluting stent

30 Mar 2026

Nicola Ryan provides her take on the 10-year follow-up of the HOST-EXAM, which was presented by Hyo-Soo Kim at ACC.26 in New Orleans.

Nicola Ryan

Author

Nicola Ryan
10-year follow-up of clopidogrel vs aspirin monotherapy in stable coronary artery disease after percutaneous coronary intervention with drug-eluting stent
Didn’t find what you were looking for?